clinical trial · NCT07204275
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Vertex Pharmaceuticals Incorporated·phase3·recruiting·n = 176
Primary Membranous NephropathyPovetaciceptTacrolimus
brief summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
started
Sep 30, 2025
primary completion
Dec 29, 2028
completion
Dec 29, 2028
last updated
Apr 24, 2026
official title
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol